IOVA Stock Overview
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Iovance Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.50 |
| 52 Week High | US$14.23 |
| 52 Week Low | US$2.70 |
| Beta | 1.05 |
| 1 Month Change | 16.67% |
| 3 Month Change | -37.94% |
| 1 Year Change | -74.32% |
| 3 Year Change | -75.80% |
| 5 Year Change | -90.31% |
| Change since IPO | -32.80% |
Recent News & Updates
US Launch And Global Expansion Will Create New Opportunities
Apr 22 The U.S. launch of Amtagvi and international expansion could drive significant revenue and market growth, enhancing revenue streams and market share.Iovance Biotherapeutics: Only For The Brave
Apr 22Iovance: The Company Makes It Hard To Estimate Revenue Growth
Mar 18Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 02
Recent updates
US Launch And Global Expansion Will Create New Opportunities
Apr 22 The U.S. launch of Amtagvi and international expansion could drive significant revenue and market growth, enhancing revenue streams and market share.Iovance Biotherapeutics: Only For The Brave
Apr 22Iovance: The Company Makes It Hard To Estimate Revenue Growth
Mar 18Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 02Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Feb 28Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Jan 11Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't
Dec 17Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Nov 11Iovance Biotherapeutics: Moving To The Next Phase
Oct 03Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Sep 06Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Aug 11Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Aug 11Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Jun 26Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
Sep 27Iovance submits rolling license application to FDA for skin cancer treatment lifileucel
Aug 25Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Aug 25Shareholder Returns
| IOVA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | 2.8% | 3.0% |
| 1Y | -74.3% | -6.8% | 10.1% |
Return vs Industry: IOVA underperformed the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: IOVA underperformed the US Market which returned 10.1% over the past year.
Price Volatility
| IOVA volatility | |
|---|---|
| IOVA Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: IOVA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IOVA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 838 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen.
Iovance Biotherapeutics, Inc. Fundamentals Summary
| IOVA fundamental statistics | |
|---|---|
| Market cap | US$1.15b |
| Earnings (TTM) | -US$372.18m |
| Revenue (TTM) | US$164.07m |
7.0x
P/S Ratio-3.1x
P/E RatioIs IOVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IOVA income statement (TTM) | |
|---|---|
| Revenue | US$164.07m |
| Cost of Revenue | US$124.00m |
| Gross Profit | US$40.08m |
| Other Expenses | US$412.25m |
| Earnings | -US$372.18m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 24.43% |
| Net Profit Margin | -226.84% |
| Debt/Equity Ratio | 0.1% |
How did IOVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 03:08 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Iovance Biotherapeutics, Inc. is covered by 23 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Colleen Kusy | Baird |
| Peter Lawson | Barclays |